{
    "organizations": [],
    "uuid": "65e5f3ebc894ddea56cf574789550122e842662b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kempharm-initiates-pivotal-efficac/brief-kempharm-initiates-pivotal-efficacy-trial-of-kp415-idUSFWN1P30P5",
    "ord_in_thread": 0,
    "title": "BRIEF-Kempharm Initiates Pivotal Efficacy Trial Of KP415",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Kempharm Inc:\n* KEMPHARM INITIATES PIVOTAL EFFICACY TRIAL OF KP415 * KEMPHARM INC - ENROLLMENT IN TRIAL IS EXPECTED TO TOTAL APPROXIMATELY 140 PATIENTS ACROSS FIVE CLINICAL SITES IN UNITED STATES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:36:00.000+02:00",
    "crawled": "2018-01-09T17:01:50.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "kempharm",
        "inc",
        "kempharm",
        "initiate",
        "pivotal",
        "efficacy",
        "trial",
        "kp415",
        "kempharm",
        "inc",
        "enrollment",
        "trial",
        "expected",
        "total",
        "approximately",
        "patient",
        "across",
        "five",
        "clinical",
        "site",
        "united",
        "state",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}